|Bid||76.25 x 1800|
|Ask||76.35 x 800|
|Day's range||75.46 - 77.44|
|52-week range||53.22 - 78.61|
|Beta (5Y monthly)||0.48|
|PE ratio (TTM)||26.97|
|Forward dividend & yield||2.16 (2.84%)|
|Ex-dividend date||31 Mar 2022|
|1y target est||N/A|
Results from a cohort of the phase II study evaluating Iovance's (IOVA) melanoma candidate were not as superior as data from another cohort of the same study.
Mirati (MRTX) posts positive data from a phase II study evaluating its lung cancer candidate adagrasib. However, the drug caused side-effects in a large number of study participants.
The European Commission approved J&J's (JNJ) BCMA-directed CAR-T cell therapy, Carvykti to treat patients with multiple myeloma who have already received multiple treatments.